CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Nanoparticle-based immunotherapy of pancreatic cancer.
Nanoparticle-based immunotherapy of pancreatic cancer.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
胰腺癌(PC)具有复杂且独特的肿瘤微环境(TME)。由于促结缔组织增生性基质形成的物理屏障,药物向肿瘤组织的递送受到限制。TME还导致对多种免疫疗法产生耐药性,如癌症疫苗、CAR-T 细胞疗法和免疫检查点抑制剂。因此,克服和/或调控TME是开发PC新治疗策略的最大挑战之一。纳米颗粒已成功用作癌症治疗中的药物载体和递送系统。近年来纳米技术的实验和工程进展使得PC的药物递送增加并改善了免疫治疗。在这篇综述中,我们讨论并分析了当前处于临床应用边缘的基于纳米颗粒的免疫治疗方法。特别是,我们重点关注提高PC免疫治疗有效性的基于纳米颗粒的递送系统。我们还强调了当前有助于开发PC新治疗策略的临床研究,尤其是基于免疫检查点抑制剂的靶向免疫治疗。
Pancreatic cancer (PC) has a complex and unique tumor microenvironment (TME). Due to the physical barrier formed by the desmoplastic stroma, the delivery of drugs to the tumor tissue is limited. The TME also contributes to resistance to various immunotherapies such as cancer vaccines, chimeric antigen receptor T cell therapy and immune checkpoint inhibitors. Overcoming and/or modulating the TME is therefore one of the greatest challenges in developing new therapeutic strategies for PC.
Nanoparticles have been successfully used as drug carriers and delivery systems in cancer therapy. Recent experimental and engineering developments in nanotechnology have resulted in increased drug delivery and improved immunotherapy for PC. In this review we discuss and analyze the current nanoparticle-based immunotherapy approaches that are at the verge of clinical application. Particularly, we focus on nanoparticle-based delivery systems that improve the effectiveness of PC immunotherapy.
We also highlight current clinical research that will help to develop new therapeutic strategies for PC and especially targeted immunotherapies based on immune checkpoint inhibitors.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。